Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Capital Expenditures (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Capital Expenditures for 11 consecutive years, with $492000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures rose 106.52% to $492000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $5.5 million, a 543.92% increase, with the full-year FY2025 number at $5.5 million, up 543.92% from a year prior.
  • Capital Expenditures was $492000.0 for Q4 2025 at Cartesian Therapeutics, down from $4.3 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $5.5 million in Q3 2024 to a low of -$7.5 million in Q4 2024.
  • A 5-year average of $400473.7 and a median of $64000.0 in 2023 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: skyrocketed 8315.38% in 2021, then tumbled 11882.81% in 2024.
  • Cartesian Therapeutics' Capital Expenditures stood at $1.1 million in 2021, then crashed by 111.99% to -$128000.0 in 2022, then soared by 150.0% to $64000.0 in 2023, then crashed by 11882.81% to -$7.5 million in 2024, then surged by 106.52% to $492000.0 in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Capital Expenditures are $492000.0 (Q4 2025), $4.3 million (Q3 2025), and -$387000.0 (Q2 2025).